Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.
About HIVE Digital Technologies Ltd. HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback